Tech Company Financing Transactions
Ivantis Funding Round
RA Capital and Merieux Developpement invested in a $25 million Series C venture round for Ivantis. The round closed on 1/11/2017.
Transaction Overview
Company Name
Announced On
1/11/2017
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series C
Investors
RA Capital (Lead Investor) (Peter Kolchinsky)
Proceeds Purpose
The funds will extend Ivantis' runway into 2020 and will support US commercialization of the Hydrus Microstent upon its anticipated 2018 US Food and Drug Administration (FDA) Approval.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
201 Technology
Irvine, CA 92618
USA
Irvine, CA 92618
USA
Phone
Website
Email Address
Overview
Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dave Meter
Chief Scientific Officer
Brett Trauthen
VP - Marketing
Michael Chodzko
VP - Operations
Todd Abraham
VP - R & D
Ken Galt
VP - Regulatory Affairs
Helene Spencer
VP - Sales
Frank Shields
Browse more venture capital transactions:
Prev: 1/11/2017: Poln venture capital transaction
Next: 1/11/2017: MobileCause venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs